Protective effects of olmesartan and <scp>l</scp>-carnitine on doxorubicin-induced cardiotoxicity in rats

Aziz, Malek M.; Fattah, Mai A. Abd El; Ahmed, Kawkab A.; Sayed, Helmy M.

doi:10.1139/cjpp-2019-0299

Cited by 33 publications

(17 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Noteworthy, plant derived-natural products have been extensively applied in improving DOX side effects. These agents enhance activity of antioxidant enzymes such as superoxide dismutase (SOD) and glutathione (GSH), while they diminish malondialdehyde (MDH) levels in preventing cardiotoxicity [95], through upregulation of Nrf2 signaling pathway [96].…”

Section: Doxorubicin: Cancer Resistance and Side Effectsmentioning

confidence: 99%

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

et al. 2020

View full text Add to dashboard Cite

Doxorubicin (DOX) is a well-known chemotherapeutic agent extensively applied in the field of cancer therapy. However, similar to other chemotherapeutic agents such as cisplatin, paclitaxel, docetaxel, etoposide and oxaliplatin, cancer cells are able to obtain chemoresistance that limits DOX efficacy. In respect to dose-dependent side effect of DOX, enhancing its dosage is not recommended for effective cancer chemotherapy. Therefore, different strategies have been considered for reversing DOX resistance and diminishing its side effects. Phytochemical are potential candidates in this case due to their great pharmacological activities. Curcumin is a potential antitumor phytochemical isolated from Curcuma longa with capacity of suppressing cancer metastasis and proliferation and affecting molecular pathways. Experiments have demonstrated the potential of curcumin for inhibiting chemoresistance by downregulating oncogene pathways such as MMP-2, TGF-β, EMT, PI3K/Akt, NF-κB and AP-1. Furthermore, coadministration of curcumin and DOX potentiates apoptosis induction in cancer cells. In light of this, nanoplatforms have been employed for codelivery of curcumin and DOX. This results in promoting the bioavailability and internalization of the aforementioned active compounds in cancer cells and, consequently, enhancing their antitumor activity. Noteworthy, curcumin has been applied for reducing adverse effects of DOX on normal cells and tissues via reducing inflammation, oxidative stress and apoptosis. The current review highlights the anticancer mechanism, side effects and codelivery of curcumin and DOX via nanovehicles.

show abstract

Section: Doxorubicin: Cancer Resistance and Side Effectsmentioning

confidence: 99%

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In accordance with our findings, it has been shown that DOX intoxication resulted in the elevation of cardiac MPO activity in DOX‐treated rats. [ 81,82 ] Our data revealed that treatment with TRE alone or in combination with DOX significantly reduced the myocardial MPO activities as compared to the DOX‐treated group. Hence, it is plausible that TRE decreased MPO‐induced ROS generation and, accordingly, reduced the myocardial damage in DOX‐treated mice.…”

Section: Discussionmentioning

confidence: 77%

Trehalose alleviates doxorubicin‐induced cardiotoxicity in female Swiss albino mice by suppression of oxidative stress and autophagy

Abu-Khudir

Ibrahim

Shams

et al. 2021

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Clinically, the use of doxorubicin (DOX) is limited due to DOX-induced cardiotoxicity (DIC). The current study aimed to evaluate the cardioprotective effect of trehalose (TRE) against DIC in a female Swiss albino mouse model. Mice were divided into five experimental groups: Gp. I: saline control group (200 μl/mouse saline three times per week for 3 weeks day after day), Gp. II: DOX-treated group (2 mg/kg body weight three times per week for 3 weeks day after day), Gp. III: TRE group (200 μg/mouse three times per week for 3 weeks day after day), Gp. IV: DOX + TRE cotreatment group (animals were coadministered with DOX and TRE as in Gp. II and III, respectively), and Gp. V: DOX + TRE posttreatment group (animals were treated with DOX as in Gp. II followed by treatment with TRE as in Gp. III). DOX-treated mice showed significant elevation in cardiac injury biomarkers (lactate dehydrogenase, creatine kinase isoenzyme-MB, and cardiac troponin I), cardiac oxidative stress (OS) markers (malondialdehyde and myeloperoxidase), and cardiac levels of autophagyrelated protein 5. Moreover, DOX significantly reduced the levels of total antioxidant capacity and activities of catalase and glutathione S-transferase.In contrast, TRE treatment of DOX-administered mice significantly improved almost all of the above-mentioned assessed parameters. Furthermore, histopathological changes of cardiac tissues observed in mice treated with TRE in combination with DOX were significantly improved as compared to DOXtreated animals. Taken together, the present study provides evidence that TRE has cardioprotective effects against DIC, which is likely mediated via suppression of OS and autophagy.

show abstract

“…Moreover, doxorubicin-induced oxidative stress can affect LPO and activate lysosomal enzymes, leading to promote the inflammation in heart tissue [ 15 ]. It has also been reported that the doxorubicin administration upregulates proinflammatory mediators of TNF- α , intercellular adhesion molecule-1 (ICAM-1), cyclooxygenase-2 (COX-2), TGF- β , nuclear factor-kappa B (NF- κ B), MPO, IL-1 β , and IL-6 levels in the cardiac cells [ 44 , 46 , 49 , 53 , 121 ]. ICAM-1 is a surface protein that is able to infiltrate leucocytes to the damaged regions of heart tissue [ 122 ].…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin‐Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti‐Inflammatory Activities

Lan

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Purpose. Although doxorubicin chemotherapeutic drug is commonly used to treat various solid and hematological tumors, its clinical use is restricted because of its adverse effects on the normal cells/tissues, especially cardiotoxicity. The use of resveratrol may mitigate the doxorubicin-induced cardiotoxic effects. For this aim, we systematically reviewed the potential chemoprotective effects of resveratrol against the doxorubicin-induced cardiotoxicity. Methods. In the current study, a systematic search was performed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline for the identification of all relevant studies on “the role of resveratrol on doxorubicin-induced cardiotoxicity” in the electronic databases of Web of Science, PubMed, and Scopus up to March 2021 using search terms in their titles and abstracts. Two hundred and eighteen articles were screened in accordance with a predefined set of inclusion and exclusion criteria. Finally, 33 eligible articles were included in this systematic review. Results. The in vitro and in vivo findings demonstrated a decreased cell survival, increased mortality, decreased heart weight, and increased ascites in the doxorubicin-treated groups compared to the control groups. The combined treatment of resveratrol and doxorubicin showed an opposite pattern than the doxorubicin-treated groups alone. Furthermore, this chemotherapeutic agent induced the biochemical and histopathological changes on the cardiac cells/tissue; however, the results (for most of the cases) revealed that these alterations induced by doxorubicin were reversed near to normal levels (control groups) by resveratrol coadministration. Conclusion. The results of this systematic review stated that coadministration of resveratrol alleviates the doxorubicin-induced cardiotoxicity. Resveratrol exerts these chemoprotective effects through several main mechanisms of antioxidant, antiapoptosis, and anti-inflammatory.

show abstract

Protective effects of olmesartan and l-carnitine on doxorubicin-induced cardiotoxicity in rats

Cited by 33 publications

References 58 publications

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

Trehalose alleviates doxorubicin‐induced cardiotoxicity in female Swiss albino mice by suppression of oxidative stress and autophagy

A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin‐Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti‐Inflammatory Activities

Contact Info

Product

Resources

About